TY - JOUR T1 - Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting rapid test JF - medRxiv DO - 10.1101/2021.03.25.21252280 SP - 2021.03.25.21252280 AU - Ducrest P.J. Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21252280.abstract N2 - There is an urgent need in rapid diagnostic test (RDT) to detect antigen of SARS-CoV-2 to reduce the spread of COVID-19 outbreak. We have developed a rapid and simple point-of-care lateral flow immunoassay (LFIA) detecting nucleocapsid antigen of SARS-CoV-2 in 10 minutes. The aim of this study is to evaluate the diagnostic performance and analytical sensitivity of this RDT. RT-PCR positive nasopharyngeal swab samples (n=20) for SARS-CoV-2 and 40 negative control samples were studied. Analytical sensitivity was assessed using Gamma-irradiated SARS-CoV-2 and the limit of detection (LOD) was determined at 1.4 × 102 TCID50/ml. Overall, RDT diagnostic sensitivity was 90% (95% confidence interval [95%CI]: 67-98%) and specificity 98% (95% CI: 85-100%). The sensitivity was 100% (95% CI: 75-100%) when using only samples with a RT-PCR Cycle threshold lower than 30. This antigen RDT displays a high diagnostic accuracy for SARS-CoV-2 antigen detection in high COVID-19 prevalence settings. Its use could be considered in the absence of routine RT-PCR facilities such in low-income countries.Competing Interest StatementPJD is the CEO of GaDia SA, the developer and manufacturer of this RDT.Funding StatementThis study was funded by GaDia SA, Switzerland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was evaluated by the Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign leftover samples. All necessary patient/participant consent has been obtained by the supplier of the samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in Supplementary material ER -